



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

AUG 08 2002

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/712,338	11/13/2000	Alexander Blinkovsky	4990.210-US

Novo Nordisk Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616

CONFIRMATION NO. 8547

FORMALITIES LETTER



OC00000008374557

Date Mailed: 06/28/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



#H

Attachment Docket No.: 4990.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Blinkovsky et al.

Confirmation No: 8547

Serial No.: 09/712,338

Group Art Unit: 1633

Filed: November 13, 2000

Examiner: To be assigned

For: Carboxypeptidases and Nucleic Acids Encoding Same

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE RULES

USPTO

Box Sequence

P.O. Box 2327

Arlington, VA 22202

Sir:

In response to the Notice to Comply with Sequence Rules dated **June 28, 2002**, please amend the above-identified application as follows (a marked up version pursuant to 37 C.F.R. 1.21 is attached hereto):

REMARKS

Applicants also enclose a paper copy and computer readable form of a Sequence Listing. I hereby state that the content of the paper and computer readable form is the same. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.


Respectfully submitted,

Date: August 5, 2002

Robert L. Starnes, Reg. No.: 41,324
Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100

should have recited "U.S. application serial no. **08/726,880** filed on October 4, 1996, now abandoned". Also, U.S. application serial no. 08/943,714 has now issued as U.S. patent no. 6,187,578, so the cross-reference was updated.

Respectfully submitted,



Robert L. Starnes, Reg. No. 41,324
Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616-4880
(530) 757-8100

Date: August 5, 2002